Related Experiment Video
Updated: Jun 23, 2026
03:40
Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
Published on: December 8, 2023
Romiplostim: a second-generation thrombopoietin agonist
Claudia S Cohn1, James B Bussel
1Department of Pathology, NY Presbyterian Hospital, New York, NY, USA.
Drugs of Today (Barcelona, Spain : 1998)
|May 14, 2009
Summary
Thrombopoietin (TPO) therapies aim to increase platelet counts. Newer TPO mimetics show promise for thrombocytopenia, avoiding antibody issues seen with earlier recombinant TPO drugs.
Area of Science:
- Hematology
- Pharmacology
- Biotechnology
Background:
- Thrombopoietin (TPO) is the primary regulator of megakaryopoiesis and platelet production.
- First-generation recombinant TPO therapies (rhTPO, PEG-rHuMGDF) increased platelet counts but caused neutralizing antibodies and failed in myeloablated patients.
Purpose of the Study:
- To review the development and clinical efficacy of TPO-based therapies for thrombocytopenia.
- To highlight advancements in second-generation TPO growth factors and mimetics.
Main Methods:
- Screening of peptide and nonpeptide libraries to identify TPO receptor agonists.
- Conjugation of peptides to carrier molecules (e.g., IgG Fc) to enhance half-life.
- Development of small molecule TPO receptor agonists and TPO-mimicking antibodies.
Main Results:
- Second-generation TPO mimetics like romiplostim, eltrombopag, and AKR-501 demonstrate efficacy in clinical trials.
- These newer agents have not elicited neutralizing antibodies, unlike earlier TPO drugs.
- Potential side effects include thromboembolic events and reversible bone marrow reticulin increases with some agents.
Conclusions:
- Second-generation TPO mimetics represent a significant advancement in treating thrombocytopenia.
- These novel therapies offer improved safety profiles compared to first-generation TPO agents.
- Ongoing research and development promise new therapeutic options for patients with low platelet counts.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
02:45Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...